P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.
Overview
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk is a phase 3 interventional study registered as NCT06468033 by PharmaEssentia, with 160 participants enrolled, started 2025-07-18 and due to reach its primary completion in 2027-11-18. Interventions recorded: Ropeginterferon alfa-2b, Placebo. Conditions listed: Primary Myelofibrosis, Myeloproliferative Neoplasm. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialA Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialA Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialRopeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Shares Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialPROUD-PV and CONTINUATION-PV
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TermAquagenic pruritus
Shares Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TermJAK2 V617F
Shares Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).